For the Inventor, By the Inventor

Enter assignee name

Pasadena, CA, United States of America

Arrowhead Research Corporation

USPTO Granted Patents = 18

% Expired Patents = 22.2

EPO Patents = 7

Trademarks = 1

Forward Citations = 23

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Jon E Chatterton (9 out of 47 patents)

Abbot F Clark (3 out of 58 patents)

Gregory Hinkle (2 out of 99 patents)

4. Stuart Milstein (2 out of 94 patents)

5. Michael Houghton (2 out of 110 patents)

6. Emma Hickman (2 out of 20 patents)

7. John M Yanni (2 out of 53 patents)

8. Daniel A Gamache (2 out of 38 patents)

9. Steven T Miller (2 out of 28 patents)

10. Martin B Wax (2 out of 15 patents)

11. Jang Hyun Han (2 out of 19 patents)

12. Satyanarayana Kuchimanchi (1 out of 40 patents)

13. Markus Hossbach (1 out of 20 patents)

14. Gino Van Heeke (1 out of 20 patents)

15. Henry Luke Danahay (1 out of 13 patents)

18 patents: Sort by Forward Citations

1. 9371529 - RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions (2016-06-21),

2. 9347062 - Interfering RNA delivery system and uses thereof (2016-05-24),

3. 9289514 - Low density lipoprotein receptor-mediated siRNA delivery (2016-03-22),

4. 9233170 - Interfering RNA delivery system and uses thereof (2016-01-12),

5. 9206428 - RNAi-mediated inhibition of histamine receptor H1-related conditions (2015-12-08),

6. 9173896 - RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions (2015-11-03),

7. 9150862 - siRNA targeting VEGFA and methods for treatment in vivo (2015-10-06),

8. 9139834 - RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis (2015-09-22),

9. 9139833 - Modified small interfering RNA molecules and methods of use (2015-09-22),

10. 9133462 - dsRNA for treating viral infection (2015-09-15),

11. 9114152 - Transferrin/transferrin receptor-mediated siRNA delivery (2015-08-25),

12. 9096637 - Organic compositions to treat HSF1-related diseases (2015-08-04),

13. 9084808 - Modified small interfering RNA molecules and methods of use (2015-07-21),

14. 9080175 - Organic compositions to treat Beta-ENaC-related diseases (2015-07-14),

15. 9074212 - RNAi inhibition of alpha-ENaC expression (2015-07-07),

Company Overview

Arrowhead Research Corporation, based in Pasadena, California, is a biotechnology company focused on developing innovative therapies for the treatment of various diseases. The organization specializes in RNA interference (RNAi) technology, which aims to silence disease-causing genes. Arrowhead's research encompasses a range of therapeutic areas, including liver diseases and other serious conditions, leveraging its proprietary platform to advance drug candidates through preclinical and clinical stages.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

18 Patents

#33 in Pasadena, CA

#4,288 in California

#17,963 in US

#34,217 in the World

Pasadena, CA, United States of America

Arrowhead Research Corporation

Forward Citations = 23

49 inventors:

Jon E Chatterton (9 out of 47 patents)

Abbot F Clark (3 out of 58 patents)

Gregory Hinkle (2 out of 99 patents)

4. Stuart Milstein (2 out of 94 patents)

5. Michael Houghton (2 out of 110 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Arrowhead Research Corporation. Retrieved from https://idiyas.com/company/arrowhead-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…